Although hormonal therapy usually exerts its action on endocrine glands, selective estrogen receptor modulators (SERM) such as tamoxifen, and selective estrogen receptor degrader (SERD) such as fulvestrant, mainly target proteins located within the tumor cell cytoplasm [15, 16]. The gene discussed is ESR1; the disease is neoplasm.